Belite Bio Inc expected to post a loss of 37 cents a share - Earnings Preview
12/05/2025 21:04
Belite Bio Inc BLTE.OQ BLTE.O is expected to show no change in quarterly revenue when it reports results on May 14 for the period ending March 31 2025 LSEG's mean analyst estimate for Belite Bio Inc is for a loss of 37 cents per share. The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Belite Bio Inc is $90.00, above its last closing price of $61.10. Previous quarterly performance (using preferred earnings measure in US dollars).
| QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
| Dec. 31 2024 | -0.29 | -0.31 | -0.32 | Missed | -4 |
| Sep. 30 2024 | -0.29 | -0.29 | -0.28 | Beat | 2.8 |
| Jun. 30 2024 | -0.27 | -0.25 | -0.31 | Missed | -22.7 |
| Mar. 31 2024 | -0.31 | -0.28 | -0.27 | Beat | 4.9 |
| Dec. 31 2023 | -0.33 | -0.30 | -0.25 | Beat | 16.7 |
| Sep. 30 2023 | -0.36 | -0.32 | -0.40 | Missed | -24.8 |
| Jun. 30 2023 | -0.40 | -0.30 | -0.26 | Beat | 12.6 |
| Mar. 31 2023 | -0.17 | -0.20 | -0.33 | Missed | -65 |
Recent news on Belite Bio
See all newsBrief: Belite Bio Announces Uplisting To The Nasdaq Global Select Market
Brief: Belite Bio Announces Multi-Market Submission Of Marketing Authorization Applications Via The Access Consortium Pathway For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Brief: Belite Bio Announces Submission Of New Drug Application To The Ministry Of Health, Labour, And Welfare In Japan Under The Sakigake Designation System For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Belite Bio, Inc reports results for the quarter ended June 30 - Earnings Summary
Belite Bio Q2 net loss widens on higher expenses